Acotiamide

Chemical compound
  • A03FA10 (WHO) QA03FA10 (WHO)
Legal statusLegal status
  • JP: Rx-only
Pharmacokinetic dataProtein binding84.21–85.95%MetabolismUGT1A8 and 1A9 (major)Elimination half-life10.9–21.7 hoursExcretionFeces (92.7%), urine (5.3%)[1]Identifiers
  • N-{2-[bis(1-Methylethyl)amino]ethyl}-2-{[(2-hydroxy-4,5-dimethoxyphenyl)carbonyl]amino}-1,3-thiazole-4-carboxamide
CAS Number
  • 185106-16-5 ☒N
PubChem CID
  • 5282338
ChemSpider
  • 4445505 checkY
UNII
  • D42OWK5383
KEGG
  • D08838 ☒N
ChEMBL
  • ChEMBL2107723 ☒N
Chemical and physical dataFormulaC21H30N4O5SMolar mass450.55 g·mol−13D model (JSmol)
  • Interactive image
  • O=C(Nc1nc(C(=O)NCCN(C(C)C)C(C)C)cs1)c2cc(OC)c(OC)cc2O
  • InChI=1S/C21H30N4O5S/c1-12(2)25(13(3)4)8-7-22-20(28)15-11-31-21(23-15)24-19(27)14-9-17(29-5)18(30-6)10-16(14)26/h9-13,26H,7-8H2,1-6H3,(H,22,28)(H,23,24,27) checkY
  • Key:TWHZNAUBXFZMCA-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Acotiamide, sold under the brand name Acofide,[2][3] is a medication manufactured and approved in Japan for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia.[4] It acts as an acetylcholinesterase inhibitor.

References

  1. ^ "Acofide (acotiamide hydrochloride hydrate) Tablets Review Report" (PDF). Retrieved 29 December 2016.
  2. ^ Nowlan ML, Scott LJ (August 2013). "Acotiamide: first global approval". Drugs. 73 (12): 1377–83. doi:10.1007/s40265-013-0100-9. PMID 23881665. S2CID 20383853.
  3. ^ Matsunaga Y, Tanaka T, Saito Y, Kato H, Takei M (February 2014). "[Pharmacological and clinical profile of acotiamide hydrochloride hydrate (Acofide(®) Tablets 100 mg), a novel therapeutic agent for functional dyspepsia (FD)]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica (in Japanese). 143 (2): 84–94. doi:10.1254/fpj.143.84. PMID 24531902.
  4. ^ Matsueda K, Hongo M, Tack J, Aoki H, Saito Y, Kato H (June 2010). "Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage". Neurogastroenterology and Motility. 22 (6): 618–e173. doi:10.1111/j.1365-2982.2009.01449.x. PMID 20059698. S2CID 41298446.
  • v
  • t
  • e
Drugs for
functional
bowel
disorders
Antimuscarinics
Tertiary
amino group
Quaternary
ammonium
compounds
Phosphodiesterase
inhibitors
Acting on
serotonin receptors
Other
Belladonna
and derivatives
(antimuscarinics)Propulsives
  • v
  • t
  • e
Enzyme
(modulators)
ChATTooltip Choline acetyltransferase
  • Inhibitors: 1-(-Benzoylethyl)pyridinium
  • 2-(α-Naphthoyl)ethyltrimethylammonium
  • 3-Chloro-4-stillbazole
  • 4-(1-Naphthylvinyl)pyridine
  • Acetylseco hemicholinium-3
  • Acryloylcholine
  • AF64A
  • B115
  • BETA
  • CM-54,903
  • N,N-Dimethylaminoethylacrylate
  • N,N-Dimethylaminoethylchloroacetate
AChETooltip Acetylcholinesterase
BChETooltip Butyrylcholinesterase
Transporter
(modulators)
CHTTooltip Choline transporter
VAChTTooltip Vesicular acetylcholine transporter
Release
(modulators)
Inhibitors
  • SNAP-25Tooltip Synaptosomal-associated protein 25 inactivators: Botulinum toxin (A, C, E)
  • VAMPTooltip Vesicle-associated membrane protein inactivators: Botulinum toxin (B, D, F, G)
Enhancers
See also
Receptor/signaling modulators
Muscarinic acetylcholine receptor modulators
Nicotinic acetylcholine receptor modulators


Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e
Stub icon

This article about an amine is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e